Pathophysiology of congestive heart failure
- PMID: 1395215
Pathophysiology of congestive heart failure
Abstract
Congestive heart failure is a syndrome common in the United States, especially in elderly patients. The most common etiology is coronary artery disease. A number of general factors contribute to the heart failure syndrome, including loss of muscle, decreased myocardial contractility, pressure or volume overload, or restricted filling. All of these factors may play a role in a given patient as, for example, with coronary artery disease. Although systolic dysfunction with a reduced ejection fraction is the most common heart failure syndrome, up to 40% of patients may have a relatively preserved ejection fraction with diastolic dysfunction. As the heart begins to fail, a number of compensatory mechanisms are activated. These include increased heart rate, the Frank-Starling mechanism, increased catecholamines, activation of the renin-angiotensin system, and release of atrial natriuretic peptides. Although these mechanisms are initially helpful to the cardiovascular system, they frequently overshoot, initiating a vicious cycle. For example, with a decrease in cardiac output, there is a reflex increase in systemic vascular resistance in order to maintain perfusion pressure. This increase in resistance, however, acts as a load on the left ventricle and further reduces cardiac output. The best evidence for the existence of this vicious cycle is the beneficial change in hemodynamics produced by vasodilator drugs and the ACE inhibitors. Thus, an understanding of pathophysiology allows for the selection of rational therapy. An unresolved problem in heart failure patients is how best to reduce the high incidence of sudden death, which is one of the major challenges for the future.
Similar articles
-
[Pathophysiologic and diagnostic aspects of heart failure].Herz. 1990 Jun;15(3):147-57. Herz. 1990. PMID: 2198215 Review. German.
-
[Neuro-hormonal mechanisms in heart insufficiency--from physiopathology to treatment].Rev Port Cardiol. 1989 Feb;8(2):129-48. Rev Port Cardiol. 1989. PMID: 2576635 Review. Portuguese.
-
[Heart failure due to ischemia--the adaptive mechanisms].Rev Med Chir Soc Med Nat Iasi. 1999 Jan-Jun;103(1-2):16-23. Rev Med Chir Soc Med Nat Iasi. 1999. PMID: 10756879 Review. Romanian.
-
Recognized molecular mechanisms of heart failure: approaches to treatment.Rev Port Cardiol. 1998 Oct;17 Suppl 2:II79-91. Rev Port Cardiol. 1998. PMID: 9835784 Review.
-
[Neuro-hormonal mechanisms in heart failure -- from physiopathology to treatment].Rev Port Cardiol. 2001 May;20 Suppl 5:V-99-122; discussion V-123-5. Rev Port Cardiol. 2001. PMID: 11515306 Review. Portuguese.
Cited by
-
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.Cardiovasc Drugs Ther. 1994 Oct;8(5):761-8. doi: 10.1007/BF00877124. Cardiovasc Drugs Ther. 1994. PMID: 7873474 Review.
-
The Role of ARNI in Enhancing Outcomes of Cardiac Resynchronization Therapy: A Comprehensive Review.J Clin Med. 2025 Apr 16;14(8):2743. doi: 10.3390/jcm14082743. J Clin Med. 2025. PMID: 40283572 Free PMC article. Review.
-
The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy.Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12283-8. doi: 10.1073/pnas.211086598. Epub 2001 Oct 2. Proc Natl Acad Sci U S A. 2001. PMID: 11593045 Free PMC article.
-
Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure.J Muscle Res Cell Motil. 2002;23(1):93-102. doi: 10.1023/a:1019988815436. J Muscle Res Cell Motil. 2002. PMID: 12363290
-
Perindopril Improves Cardiac Function by Enhancing the Expression of SIRT3 and PGC-1α in a Rat Model of Isoproterenol-Induced Cardiomyopathy.Front Pharmacol. 2020 Feb 21;11:94. doi: 10.3389/fphar.2020.00094. eCollection 2020. Front Pharmacol. 2020. PMID: 32153406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous